Objective.-To evaluate Quality of life(QoL)of HIV-infected children under highly active antiretroviral therapies,and its change over 18 months.Material s and methods.-QoL was evaluated by self-administred questionnair...Objective.-To evaluate Quality of life(QoL)of HIV-infected children under highly active antiretroviral therapies,and its change over 18 months.Material s and methods.-QoL was evaluated by self-administred questionnaires(french v ersions of AUQUEI,OK-ado,and compilation of both)in 23 young living with HIV /AIDS(6-15 yrs),under antiretroviral multitherapies,and re-evaluated 18 mon ths later in 19 of them.Results.-At baseline,QoL in HIV-infected children-adolescents was relatively good.The answers given to each items and the mean sc ore from infected children were similar to those obtained in uninfected healthy children.Moreover,infected adolescents distinguished definitly from healthy ad olescents,describing higher QoL.The mean satisfaction score from the whole gro up decreased between M0 and M18(mainly in the youngests)-,and mainly concerne d 3 fields(self-esteem,health and school)while their somatic health remained stable or improved.An effect of the familial context was also observed for the se 3 fields.Conclusion.-The progressive decline of QoL in HIV-infected child ren,and the surprising high and steady level of satisfaction over-time provide d by the adolescents,underlined the frailty of this population and the need for a psychologic management associated to the medical follow-up.Such a multidisc iplinary approach should take into account the preoccupations and difficulties o f each age-class,those linked to the diagnosis itself,and to the familial or scolar contexts,in order to preserve QoL of this pediatric population,as far a s possible,in a long term.展开更多
Chronic diarrhea and colitis are common in patients positive for human immunodeficiency virus (HIV) under highly active antiretroviral treatment (HAART). This prospective doubleblind study explores the effect of mesal...Chronic diarrhea and colitis are common in patients positive for human immunodeficiency virus (HIV) under highly active antiretroviral treatment (HAART). This prospective doubleblind study explores the effect of mesalamine vs. placebo in HIV-positive patients. Thirteen HIV-infected patients with noninfectious chronic diarrhea and >250CD4+ cells/mm3 were randomized to mesalamine (2.4 g/day; n = 9) or placebo (n = 4) for 6 weeks. Colonoscopy was performed at baseline and week 6, and biopsies were obtained to calculate the Biopsy Activity Index (BAI). Diarrhea was assessed at baseline and end of treatment using the Disease Activity Index (DAI). Patients and clinicians completed Patient Global Improvement index (PGI) and Clinical Global Improvement index (CGI) at weeks 2 and 6. Comparisons at week 6 were statistically significant between mesalamine and placebo groups for BAI (P = 0.03), DAI (P = 0.007), PGI (P = 0.008), and CGI (P = 0.008). Furthermore, major improvements were documented in the mesalamine group at week 6 compared to baseline for all variables, whereas the placebo group did not have any. Mesalamine was effective for treatment of chronic diarrhea and moderate nonspecific colitis in HIV patients.展开更多
20世纪90年代前后,当抗逆转录病毒治疗(ART)刚刚兴起的时候, 对艾滋病的治疗原则是早治疗、早控制。随着抗逆转录病毒药物的不断出现,特别是在20世纪90年代后期高活性抗逆转录病毒治疗(HAART)的出现,使艾滋病患者的生命得到了有效地延长...20世纪90年代前后,当抗逆转录病毒治疗(ART)刚刚兴起的时候, 对艾滋病的治疗原则是早治疗、早控制。随着抗逆转录病毒药物的不断出现,特别是在20世纪90年代后期高活性抗逆转录病毒治疗(HAART)的出现,使艾滋病患者的生命得到了有效地延长,但药物的不良反应和临床并发症成了艾滋病治疗中的主要问题。最佳治疗组合的选择、药物间的相互作用和新的治疗策略成了控制艾滋病的主要研究重点,并取得了许多新的进展。2006年2月5～8日在美国科罗拉多州丹佛市召开的“第13届抗逆转录病毒和机会性感染大会(The 13th Conference on Retroviruses and Opportunistic Infection,CROI)”,为控制艾滋病的国际合作提供了交流与合作的平台。本文对这次大会上反映的一些重点研究和成果作一介绍。展开更多
E2 is an envelope glycoprotein of Classical swine fever virus (CSFV) and contains sequential neutralizing epitopes to induce virus-neutralizing antibodies and mount protective immunity in the natural host. In this stu...E2 is an envelope glycoprotein of Classical swine fever virus (CSFV) and contains sequential neutralizing epitopes to induce virus-neutralizing antibodies and mount protective immunity in the natural host. In this study, four antigen domains (ABCD) of the E2 gene was cloned from CSFV Shimen strain into the retroviral vector pBABE puro and expressed in eukaryotic cell (PK15) by an retroviral gene expression system, and the activity of recombinant E2 protein to induce immune responses was evaluated in rabbits. The results indicated that recombinant E2 protein can be recognized by fluorescence antibodies of CSFV and CSFV positive serum (Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, China) using Western blot, indirect immunofluorescence antibody test (IFAT) and ELISA, Furthermore, anti-CSFV specific antibodies and lymphocyte proliferation were elicited and increased by recombinant protein after vaccination. In the challenge test, all of rabbits vaccinated with recombinant protein and Chinese vaccine strain (C-strain) were fully protected from a rabbit spleen virus challenge. These results indicated that a retroviral-based epitope-vaccine carrying the major antigen domains of E2 is able to induce high level of epitope-specific antibodies and exhibits similar protective capability with that induced by the C-strain, and encourages further work towards the development of a vaccine against CSFV infection.展开更多
Since the introduction of antiretroviral therapy (ART), the lifespan and quality of life of patients infected with HIV have been significantly improved. But treatment efficacy was compromised eventually by the develop...Since the introduction of antiretroviral therapy (ART), the lifespan and quality of life of patients infected with HIV have been significantly improved. But treatment efficacy was compromised eventually by the development of resistance to antiretroviral drugs, and more new anti-HIV drugs with lower toxicity and higher activity were needed. Based on the experience and lessons learned from the treatment in the developed countries, US FDA suggested that more pharmacodynamical researches should be considered ahead of the clinical trials. To facilitate the anti-HIV drug research and development, we reviewed a few specialized issues that should be focused on drug evaluations in vitro, including: 1) Mechanism of action studies, demonstrating the candidate drug's efficacy to specifically inhibit viral replication or a virus-specific function and confirm the drug target. 2) Drug resistance studies, selecting the drug-resistant variants in vitro and determining the activities inhibiting HIV isolates resistant to approved antiretroviral drugs of the same class. 3) Antiviral activity in vitro in the presence of serum proteins, ascertaining whether an investigational product is significantly bound by serum proteins. 4) Combination activity analysis, evaluating in vitro antiviral activity of an investigational product in two-drug combinations with other drugs approved.展开更多
文摘Objective.-To evaluate Quality of life(QoL)of HIV-infected children under highly active antiretroviral therapies,and its change over 18 months.Material s and methods.-QoL was evaluated by self-administred questionnaires(french v ersions of AUQUEI,OK-ado,and compilation of both)in 23 young living with HIV /AIDS(6-15 yrs),under antiretroviral multitherapies,and re-evaluated 18 mon ths later in 19 of them.Results.-At baseline,QoL in HIV-infected children-adolescents was relatively good.The answers given to each items and the mean sc ore from infected children were similar to those obtained in uninfected healthy children.Moreover,infected adolescents distinguished definitly from healthy ad olescents,describing higher QoL.The mean satisfaction score from the whole gro up decreased between M0 and M18(mainly in the youngests)-,and mainly concerne d 3 fields(self-esteem,health and school)while their somatic health remained stable or improved.An effect of the familial context was also observed for the se 3 fields.Conclusion.-The progressive decline of QoL in HIV-infected child ren,and the surprising high and steady level of satisfaction over-time provide d by the adolescents,underlined the frailty of this population and the need for a psychologic management associated to the medical follow-up.Such a multidisc iplinary approach should take into account the preoccupations and difficulties o f each age-class,those linked to the diagnosis itself,and to the familial or scolar contexts,in order to preserve QoL of this pediatric population,as far a s possible,in a long term.
文摘Chronic diarrhea and colitis are common in patients positive for human immunodeficiency virus (HIV) under highly active antiretroviral treatment (HAART). This prospective doubleblind study explores the effect of mesalamine vs. placebo in HIV-positive patients. Thirteen HIV-infected patients with noninfectious chronic diarrhea and >250CD4+ cells/mm3 were randomized to mesalamine (2.4 g/day; n = 9) or placebo (n = 4) for 6 weeks. Colonoscopy was performed at baseline and week 6, and biopsies were obtained to calculate the Biopsy Activity Index (BAI). Diarrhea was assessed at baseline and end of treatment using the Disease Activity Index (DAI). Patients and clinicians completed Patient Global Improvement index (PGI) and Clinical Global Improvement index (CGI) at weeks 2 and 6. Comparisons at week 6 were statistically significant between mesalamine and placebo groups for BAI (P = 0.03), DAI (P = 0.007), PGI (P = 0.008), and CGI (P = 0.008). Furthermore, major improvements were documented in the mesalamine group at week 6 compared to baseline for all variables, whereas the placebo group did not have any. Mesalamine was effective for treatment of chronic diarrhea and moderate nonspecific colitis in HIV patients.
文摘20世纪90年代前后,当抗逆转录病毒治疗(ART)刚刚兴起的时候, 对艾滋病的治疗原则是早治疗、早控制。随着抗逆转录病毒药物的不断出现,特别是在20世纪90年代后期高活性抗逆转录病毒治疗(HAART)的出现,使艾滋病患者的生命得到了有效地延长,但药物的不良反应和临床并发症成了艾滋病治疗中的主要问题。最佳治疗组合的选择、药物间的相互作用和新的治疗策略成了控制艾滋病的主要研究重点,并取得了许多新的进展。2006年2月5～8日在美国科罗拉多州丹佛市召开的“第13届抗逆转录病毒和机会性感染大会(The 13th Conference on Retroviruses and Opportunistic Infection,CROI)”,为控制艾滋病的国际合作提供了交流与合作的平台。本文对这次大会上反映的一些重点研究和成果作一介绍。
基金The National "973" (2005CB523201)Key Technology R&D Programme (2006BAD06A03)
文摘E2 is an envelope glycoprotein of Classical swine fever virus (CSFV) and contains sequential neutralizing epitopes to induce virus-neutralizing antibodies and mount protective immunity in the natural host. In this study, four antigen domains (ABCD) of the E2 gene was cloned from CSFV Shimen strain into the retroviral vector pBABE puro and expressed in eukaryotic cell (PK15) by an retroviral gene expression system, and the activity of recombinant E2 protein to induce immune responses was evaluated in rabbits. The results indicated that recombinant E2 protein can be recognized by fluorescence antibodies of CSFV and CSFV positive serum (Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, China) using Western blot, indirect immunofluorescence antibody test (IFAT) and ELISA, Furthermore, anti-CSFV specific antibodies and lymphocyte proliferation were elicited and increased by recombinant protein after vaccination. In the challenge test, all of rabbits vaccinated with recombinant protein and Chinese vaccine strain (C-strain) were fully protected from a rabbit spleen virus challenge. These results indicated that a retroviral-based epitope-vaccine carrying the major antigen domains of E2 is able to induce high level of epitope-specific antibodies and exhibits similar protective capability with that induced by the C-strain, and encourages further work towards the development of a vaccine against CSFV infection.
基金supported by Major Science and Technology Special Projects (2009 ZX09301)
文摘Since the introduction of antiretroviral therapy (ART), the lifespan and quality of life of patients infected with HIV have been significantly improved. But treatment efficacy was compromised eventually by the development of resistance to antiretroviral drugs, and more new anti-HIV drugs with lower toxicity and higher activity were needed. Based on the experience and lessons learned from the treatment in the developed countries, US FDA suggested that more pharmacodynamical researches should be considered ahead of the clinical trials. To facilitate the anti-HIV drug research and development, we reviewed a few specialized issues that should be focused on drug evaluations in vitro, including: 1) Mechanism of action studies, demonstrating the candidate drug's efficacy to specifically inhibit viral replication or a virus-specific function and confirm the drug target. 2) Drug resistance studies, selecting the drug-resistant variants in vitro and determining the activities inhibiting HIV isolates resistant to approved antiretroviral drugs of the same class. 3) Antiviral activity in vitro in the presence of serum proteins, ascertaining whether an investigational product is significantly bound by serum proteins. 4) Combination activity analysis, evaluating in vitro antiviral activity of an investigational product in two-drug combinations with other drugs approved.
